Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 June 2021Website:
http://www.januxrx.comNext earnings report:
08 May 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | Thu, 21 Nov 2024 10:34:00 GMTDividend
Analysts recommendations
Institutional Ownership
JANX Latest News
Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life. Lead candidate JANX007 demonstrates strong PSA reduction and favorable safety profile in phase 1 trials for metastatic castration-resistant prostate cancer. JANX007's innovative design addresses limitations of previous T cell engagers, showing potential for reduced toxicities and improved patient outcomes.
Janux Therapeutics (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.42 per share a year ago.
Investors seeking an adrenaline rush can easily experience it by investing in biotech stocks. There is an exciting element in investing in a company that is making critical decisions with life-saving drugs.
Janux (JANX) stock rises after reports suggest the company is considering a potential sale due to interest from major pharmaceutical companies.
Janux Therapeutics (JANX) is a promising choice for investors seeking stocks that are likely to continue their recent upward momentum, as it is among the stocks that have met our criteria for "Recent Price Strength."
Janux Therapeutics saw an increase in its stock price this week following reports that the company is considering a potential sale. The company has not confirmed or denied any ongoing acquisition talks.
Analysts' price targets for Janux Therapeutics (JANX) suggest a 40.3% potential increase in the stock. Although this widely-used measure may not always be accurate, the consensus among analysts in raising earnings estimates does indicate a positive outlook for the stock.
According to a media report, the biotech company is exploring the possibility of selling itself and has received buyout offers from pharmaceutical companies.
Janux Therapeutics (JANX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 1(current)
What type of business is Janux Therapeutics?
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
What sector is Janux Therapeutics in?
Janux Therapeutics is in the Healthcare sector
What industry is Janux Therapeutics in?
Janux Therapeutics is in the Biotechnology industry
What country is Janux Therapeutics from?
Janux Therapeutics is headquartered in United States
When did Janux Therapeutics go public?
Janux Therapeutics initial public offering (IPO) was on 11 June 2021
What is Janux Therapeutics website?
https://www.januxrx.com
Is Janux Therapeutics in the S&P 500?
No, Janux Therapeutics is not included in the S&P 500 index
Is Janux Therapeutics in the NASDAQ 100?
No, Janux Therapeutics is not included in the NASDAQ 100 index
Is Janux Therapeutics in the Dow Jones?
No, Janux Therapeutics is not included in the Dow Jones index
When was Janux Therapeutics the previous earnings report?
No data
When does Janux Therapeutics earnings report?
The next expected earnings date for Janux Therapeutics is 08 May 2025